Annexon anticipates a Biologics License Application (BLA) submission for ANX005 in the first half of 2025, potentially transforming Guillain-Barré Syndrome (GBS) treatment.
Annexon Biosciences completed a pivotal Phase 3 trial for ANX005, an immunotherapy targeting C1q, showing statistically significant results on key endpoints for Guillain-Barré Syndrome (GBS).